Main provisions of the ESC recommendation swith the problem of cardioncology (2022). Part 3. Treatment of cardiovascular complications of anticancer therapy and long-term follow-up
No. 1 (2024), REVIEW OF CLINICAL RECOMMENDATIONS OF PROBLEMS OF INTERNAL MEDICINE
No. 1 (2024)

Main provisions of the ESC recommendation swith the problem of cardioncology (2022). Part 3. Treatment of cardiovascular complications of anticancer therapy and long-term follow-up

REVIEW OF CLINICAL RECOMMENDATIONS OF PROBLEMS OF INTERNAL MEDICINE
Published March 29, 2024
M.Y. Fedechko
Львівський національний медичний університет ім. Данила Галицького
M.P Halkevych
Львівський національний медичний університет ім. Данила Галицького
N.V. Chmyr
Львівський національний медичний університет ім. Данила Галицького
pdf (Українська)

Keywords

cardiotoxicity, anthracyclines, HER2-targeted therapies, immune checkpoint inhibitors, cardiac biomarkers, ECG, Echocardiography, chemotherapy, coronary artery disease, acute coronary syndrome, arterial hypertension, atrial fibrillation

How to Cite

Fedechko, M., Halkevych, M., & Chmyr, N. (2024). Main provisions of the ESC recommendation swith the problem of cardioncology (2022). Part 3. Treatment of cardiovascular complications of anticancer therapy and long-term follow-up. The Practitioner, (1), 11-19. Retrieved from https://plr.com.ua/index.php/journal/article/view/792
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX

Abstract

Diagnosis and treatment of cancer therapy-related cardiovascular complications is a frequent problem that affects the quality of life of patients with cancer and requires complex approaches. Questions about the continuation/restoration of anticancer treatment are accepted by multidisciplinary teams, and are based on clinical data, the results of examinations and risk assessment. In cancer patients there is a high risk of developing heart failure, triggered by the cardiotoxicity of some anti-cancer medications, in particular anthracyclines, and checkpoint inhibitors enhance the development of myocarditis, which is based on immune processes. A significant role in the occurrence of complications is played by the so-called tumor-associated thrombosis, which can be both arterial (myocardial infarction, ischemic stroke) and venous (pulmonary embolism, peripheral thrombosis). The treatment and prevention of these thromboses are a common clinical problem, since oncological pathology might predict a high risk of bleeding due to сhemotherapy-induced thrombocytopenia. They can also be caused by malignant neoplasms or metastases. Patients undergoing cardiotoxic chemotherapy or chest irradiation have a several times higher risk of adverse events, such as coronary artery disease, chronic heart failure. They should undergo long term follow-up and control of the cardiovascular system.

pdf (Українська)

References

1. Agnelli G, Gussoni G, Bianchini C, Verso M, Mandalà M, Cavanna L, et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol. 2009;10:943-949.
2. Armenian SH, Hudson MM, Mulder RL, Chen MH, Constine LS, Dwyer M, et al. Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol. 2015;16:e123-e136.
3. Atallah-Yunes SA, Kadado AJ, Kaufman GP, Hernandez-Montfort J. Immune checkpoint inhibitor therapy and myocarditis: a systematic review of reported cases. J Cancer Res Clin Oncol. 2019;145:1527-1557.
4. Barac A, Murtagh G, Carver JR, Chen MH, Freeman AM, Herrmann J, et al. Cardiovascular health of patients with cancer and cancer survivors: a roadmap to the next level. J Am Coll Cardiol. 2015;65:2739-2746.
5. Bharadwaj AS, Swamy PM, Mamas MA. Outcomes of percutaneous coronary interventions in cancer patients. Expert Rev Cardiovasc Ther. 2020;18:25-32.
6. Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015;131:1981-1988.
7. Carrier M, Abou-Nassar K, Mallick R, Tagalakis V, Shivakumar S, Schattner A, et al. Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med. 2019;380:711-719.
8. Collet J-P, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42:1289-1367.
9. Curigliano G, Lenihan D, Fradley M, Ganatra S, Barac A, Blaes A, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020;31:171-190.
10. Delombaerde D, Vervloet D, Franssen C, Croes L, Gremonprez F, Prenen H, et al. Clinical implications of isolated troponinemia following immune checkpoint inhibitor therapy. ESMO Open. 2021;6:100216.
11. D’Souza M, Carlson N, Fosbøl E, Lamberts M, Smedegaard L, Nielsen D, et al. CHA2DS2-VASC score and risk of thromboembolism and bleeding in patients with atrial fibrillation and recent cancer. Eur J Prev Cardiol. 2018;25:651-658.
12. Farmakis D, Parissis J, Filippatos G. Insights into onco-cardiology: atrial fibrillation in cancer. J Am Coll Cardiol. 2014;63:945-953.
13. Fidler MM, Reulen RC, Henson K, Kelly J, Cutter D, Levitt GA, et al. Population-based long-term cardiac-specific mortality among 34 489 five-year survivors of childhood cancer in Great Britain. Circulation. 2017;135:951-963.
14. Fradley MG, Beckie TM, Brown SA, Cheng RK, Dent SF, Nohria A, et al. Recognition, prevention, and management of arrhythmias and autonomic disorders in cardio-oncology: a scientific statement from the American Heart Association. Circulation. 2021;144:E41-E55.
15. Gevaert SA, Halvorsen S, Sinnaeve PR, Sambola A, Gulati G, Lancellotti P, et al. Evaluation and management of cancer patients presenting with acute cardiovascular disease: a Consensus Document of the Acute CardioVascular Care (ACVC) association and the ESC council of Cardio-Oncology − Part 1: acute coronary syndromes and acute pericardial diseases. Eur Heart J Acute Cardiovasc Care. 2021; 10:947-959.

Downloads

Download data is not yet available.